Lansoprazole Krka

Lansoprazole, the active ingredient in Lansoprazole Krka, is a proton pump inhibitor presented as an oral dosage form for oral use. It works by inhibiting gastric acid secretion and is indicated for the treatment of gastro‑oesophageal reflux disease, peptic ulcer disease, erosive esophagitis and as part of Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Lansoprazole Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines across multiple markets.

Lansoprazole is a proton pump inhibitor that reduces gastric acid production, making it useful for several acid‑related gastrointestinal disorders.

- Gastro‑oesophageal reflux disease (GERD): relieves heartburn and promotes healing of esophageal erosion. - Peptic ulcer disease: accelerates ulcer healing and helps prevent recurrence. - Erosive esophagitis: reduces inflammation and facilitates mucosal repair. - Helicobacter pylori eradication: used in combination therapy to improve eradication success.

Lansoprazole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Clostridioides difficile infection - Low magnesium levels (hypomagnesemia) - Bone fractures with long‑term use - Acute interstitial nephritis - Elevated liver enzymes

When prescribing Lansoprazole, clinicians should consider several safety measures.

- Assess renal function: dose adjustment may be needed in severe renal impairment. - Monitor for infection: prolonged use can increase risk of gastrointestinal infections. - Avoid long‑term use without supervision: may be linked to bone fracture risk. - Check magnesium levels: prolonged therapy can cause hypomagnesemia. - Pregnancy and lactation: use only if benefit outweighs risk (category unknown). - Store at room temperature: keep in original container, protect from moisture and light.

Lansoprazole can affect the pharmacokinetics of several medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption of atazanavir. - Methotrexate: increased toxicity. - Warfarin: potential increase in INR. - Ketoconazole: reduced antifungal efficacy.

Moderate Interactions (Monitor Closely): - Diazepam: increased plasma levels. - Digoxin: possible increase in serum concentration. - Iron supplements: decreased absorption if taken concurrently. - Vitamin B12: reduced absorption with long‑term use. - HIV protease inhibitors: may require dose adjustment.